
Heart Failure with Preserved Ejection Fraction (Diastolic CHF) and SGLT-2 Inhibitor Therapy
0:00
11:32
The double-blind, randomized phase III EMPEROR-Preserved trial showed a benefit of the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF).
Now let us dig a bit more into those headlines.
More episodes from "Hospital and Internal Medicine Podcast"



Don't miss an episode of “Hospital and Internal Medicine Podcast” and subscribe to it in the GetPodcast app.







